Andreas Halvorsen's Viking Global has liquidated its entire position in medical technology firm Edwards Lifesciences (EW). According to a quarterly disclosure filed with the SEC, the fund sold off its 1.10 million shares, a stake previously valued at $87.89 million. It is important to remember that these 13F filings are released with a delay, so this report reflects trades made between March 31 and June 30, 2026, and not necessarily current market activity.
Edwards Lifesciences recently reported its second-quarter results on July 23, 2026, showing a 13.6% increase in year-over-year sales and raising its guidance for the full year. The company is a major player in heart valve technology and other structural heart treatments. Viking Global's exit from this position represents a notable change for the investment firm, which had re-established a position in the company in the first quarter of 2026.